AUTHORS
Elizabeth Florence Krakow, MD,CM, MSc, Folashade Otegbeye, MBBChir,MPH2, Michelle Choe, MD3, Corinne Summers, MD4, Melinda A Biernacki, MD5, Elizabeth Frecker6, Nicole Vartanian7, Andrew Smoack8, Graeme Black9, Marie Bleakley Jr, PhD, MBBS, MMSc10
AFFILIATIONS
1 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
6 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
9 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Background: Relapse after allogeneic hematopoietic cell transplantation (HCT) for acute leukemias and related hematologic malignancies carries a poor prognosis. The minor histocompatibility antigen HA-1 is an attractive target for post-HCT T-cell therapy: the immunogenic HA-1H peptide is presented by HLA-A*02:01 and arises from a single nucleotide polymorphism in HMHA1, which encodes a RhoGAP protein restricted to hematopoietic tissue. HA-1H-directed T cells (manufactured from HA-1R/R or HLA-A2-negative HCT donors) are therefore expected to mediate a graft-versus-leukemia effect with low risk of graft-versus-host disease (GVHD). We isolated a high-avidity HA-1H/HLA-A*02:01-specific T-cell receptor (TCR), cloned it into a lentiviral vector incorporating a CD8 co-receptor, an inducible caspase-9 (iCasp9) safety switch, and an RQR selection/tracking element, and used it to engineer donor-derived memory T cells (Dossa et al, Blood 2018, PMID 29051183).
Study Design and Methods: This is an open-label, single-arm, non-randomized phase I feasibility study (NCT0332692) conducted at the Fred Hutchinson Cancer Center and Seattle Children's Hospital. Primary endpoints are feasibility of manufacturing HA-1 TCR CD8+ and CD4+ memory T cells and dose-limiting toxicity (DLT). Secondary endpoints include in vivo persistence in blood and marrow, cytolytic function, reduction in leukemia burden, improvement in recipient chimerism, GVHD, and the recommended phase 2 dose.
Eligible subjects are children and adults (ages 0–80) with persistent or recurrent AML, ALL, mixed-phenotype AL, CML with prior blast crisis, MDS, MPN, CMML, JMML, lymphoma or myeloma after allogeneic HCT, who have HLA-A*02:01 and HA-1H (RS_1801284 A/A or A/G) genotype, with a HCT donor who lacks either HLA-A2 or HA-1H (i.e., has HA-1R , genotype G/G). Initial enrollment may occur before or after HCT. Production of HA-1 TCR T cells from leukapheresis-derived donor memory T cells occurs in the Fred Hutch GMP facility. Subjects receive lymphodepleting chemotherapy followed by a single intravenous HA-1 TCR T-cell infusion, with potential subsequent infusions. Subjects are divided into two groups (<16 and ≥16 years) with independent dose escalation/de-escalation in cohorts of 3. The MTD is defined as the maximum dose associated with a DLT rate ≤33%. Approximately 24 subjects will be treated.
Following analysis of the initial cohort (Krakow et al, Blood 2024, PMID 38683966), in which 4 of 9 subjects met protocol-defined response criteria, including 2/2 at dose level 3, the protocol has been amended in three ways. First, the dose-escalation schema has been extended with two additional dose levels (DL)— DL4 (up to 100 × 106 cells/kg) and DL5 (up to 300 × 106 cells/kg)—above the prior maximum of dose level 3 (up to 30 × 106 cells/kg). Second, manufacturing was modified to co-culture CD4+ and CD8+ cells throughout (rather than isolating, culturing them separately and combining them at the end of the process), with the goal of enhancing CD8+ TCR T-cell expansion and persistence at high levels. Third, lymphodepletion has been intensified to promote TCR T-cell expansion and align with regimens used before chimeric antigen receptor T-cell therapy: subjects with no detectable disease (after bridging therapy) or measurable residual disease receive fludarabine plus cyclophosphamide, while subjects with overt disease may receive an intensive purine-analogue-containing regimen (e.g., fludarabine/cytarabine ± idarubicin, clofarabine/cytarabine, or nelarabine/etoposide/cyclophosphamide for T-lineage disease).
The trial has re-opened to accrual under the amended protocol and is currently enrolling subjects ≥16 years at dose level 3 and <16 at dose level 2. Funding for travel and housing are available to facilitate out-of-state referrals.
Preliminary Outcome: The first subject under the revised protocol was a 59-year-old man with ASLX1+ MDS-IB1 who was diagnosed with measurable residual disease (MRD) relapse on day 84 after matched unrelated donor HCT, despite grade II GI GvHD diagnosed at day 42. He was treated with Flu-Cy lymphodepletion followed by infusion of 30 × 106 cells/kg, resulting in prompt peripheral blood CD3 donor chimerism improvement from 79% to 100% without GvHD flare, robust TCR T-cell expansion in blood and marrow, and disease clearance on 3 consecutive bone marrow evaluations with 7 weeks follow-up as of 7/8/2026.
DISCLOSURES
Elizabeth Florence Krakow, MD,CM, MSc: Simcha Therapeutics - Research Funding; Promicell, Inc - Research Funding